| INTRODUCTION
The age defining "very elderly" patients has been determined according to the type of treatment administered, on the basis of the outcome of clinical trials. R-CHOP can be administered until the age of 80.
Beyond this, specific considerations should be taken into account, and this threshold has thus been used to define this population. Lymphoma in very elderly patients is common because approximately half of all lymphoma cases occur in patients more than 65 years old and one-third of reported cases are aged over 75 years.
The incidence of lymphoma in older patients has increased in recent years, probably more than that of young patients, as the population aged over 60 years is continuously expanding. Although recent results showed a trend during the nineties towards stabilization of lymphoma incidence for young patients, this is not the case for older patients simply because humans are living longer and the number of older patients is consequently increasing. Very few differences have been described between young and elderly lymphoma patients in morphology and clinical presentation.
However, the outcome of elderly patients with lymphoma is worse, particularly for those with aggressive subtypes, because of the difficulties encountered during treatment and the difficulties related to the presence of other diseases, diminished organ functions, and altered drug metabolism. Until recently, very elderly patients were systematically considered too frail to receive an appropriate treatment and were thus treated with low-dose regimens. Recent studies have concluded that the best way to improve the survival of very elderly patients with lymphoma is to choose treatment based on objective scales for the disease and the patient's general status.
| INCIDENCE OF LYMPHOMA IN VERY ELDERLY PATIENTS
Life expectancy has increased dramatically over the past 50 years, with the greatest increase since the 1960s occurring between 2000 and 2015 (by 5 years). This naturally results in an increase in the number of elderly patients. Current estimates indicate that the number of people older than 65 years has more than doubled compared to 100 years ago. Individuals aged over 75 years will triple by 2030, and the group aged 85 years or older will double in the same period. This is associated with an increase in the incidence of cancer, which has been the leading cause of death, ahead of heart disease, for individuals younger than 85 years since 1999.
An increase in the incidence of lymphoma between 8% to 10% per year has been documented in Europe and the United States, particularly for patients older than 65 years, who represent half of all newly examined lymphoma patients. For the last 25 years, lymphoma incidence has increased by more than 50%, and even more than this in patients more than 60 years old, with 15 to 17 new cases a year for every 100 000 inhabitants in the United States. Several epidemiologic Summary article of Meet the Professor and Educational Symposia presentations of the 14-ICML. The copyright line for this article was changed on 9 March 2018 after original print and online publication. studies have been performed to understand this rise, in particular attempting to associate it with occupational exposures, which have 
| VARIATIONS IN BIOLOGY OF DLBCL BETWEEN YOUNG AND VERY ELDERLY PATIENTS
Since the last decade, DLBCL biology has been increasingly understood; it is known to be highly heterogeneous, the germinal center Bcell like/activated B-cell like (ABC) signature being considered the major biological determinant. Remarkably, several arguments are present in the literature showing that the biology of aging has a major impact on lymphoma biology. This includes not only the germinal center B-cell like/ABC signature, the ABC being overrepresented in patients over 80 years compared with patients aged 50 to 60 years (54% vs 33% ABC, P = .04), but also BCL2 expression or cytogenetic complexity, which increases with age at diagnosis. 
| STAGING: SPECIAL MENTION IN VERY ELDERLY PATIENTS
Given the biological complexity of these tumors, a biopsy is an essen- (Table 1) .
Specific attention must be paid to comorbidities and organ dysfunctions to assess the age-related factors. Very elderly patients frequently have comorbidities including diminished cardiac and renal function, as well as alterations in drug absorption, distribution, activation, detoxification, metabolism, and clearance, which modify the pharmacodynamics of the therapeutics. Decreases in the glomerular filtration rate and tubular reabsorption delay drug excretion, such that doses may have to be tailored to creatinine clearance.
Because of decreased liver function, the metabolism of certain drugs such as cyclophosphamide or anthracyclines may be altered. However, adjustment for hepatic function was not associated with better tolerance. Hematopoietic reserve capacity may also be altered, and myelotoxicity is thus increased with standard treatment doses compared to younger patients. 8 However, decreasing dosages because of a putative increased toxicity was proven to be associated with poorer therapeutic results. The presence of a comorbidity is associated with decreased dose intensity and decreased overall survival (OS).
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Details of this staging are presented in Table 1 .
Evaluation of lymphoma and the geriatric assessment are per- 
| TREATMENT
There is currently no standard treatment for very elderly patients because the most important point in this scenario is to define how to adapt treatment to the patient's specificities rather than to apply a unique regimen. However considerable progress has been made over the last decade, with retrospective and prospective studies placing median OS in this population in the range of 2.0 to 2.5 years. 7,10,11 A classical approach to treat these patients has been to place them into 3 groups as defined by Balducci in 2000: fit, unfit, and frail. However, the definition of these groups for lymphoma are highly dependent on the type of treatment proposed and its expected toxicities and risks, notably febrile neutropenia, cardiopathy, number and duration of hospitalizations, neuropathy, diabetes, and osteoporosis inducing early death and functional decline.
| The prephase
The use of prephase treatment associating oral vincristine (1 mg total dose 1 week before cycle 1 [day -7] ) and oral prednisone (60 mg/m 2 for 1 week) has been advocated, allowing a reduction in induction therapy-associated toxicities. 10, 12 Vincristine appears to be the least important component of this association, and prednisone alone may be proposed which should result in better tolerability, particularly in terms of toxicities in the first treatment cycle.
| Chemotherapy adapted to fit patients with DLBCL
Delivery of standard dose R-CHOP was felt to be unrealistic in the fit population, and although rituximab use was associated with decreased mortality, 1-year OS was better when anthracycline dose intensity was <85% versus >85%, perhaps related to baseline performance status.
Few prospective trials integrate a search for optimal treatment. Planned treatment was 8 courses of R-COMP. 13 Overall response rate was 71% with 57% complete response (CR), 3-year progression-free survival 69%, and 3-year OS 72% with an acceptable safety profile.
R-COMP appears to result in reduced cardiotoxicity compared to standard doxorubicin (21% cardiac event, with 4% of patients having R-bendamustine may also be proposed. However, results are worse, with only a 52% rate of complete response and short survival.
| Growth factors and febrile neutropenia
In this patient population, optimal use of myeloid growth factors remains an important means of minimizing myelosuppression and subsequent infectious complications, not only to reduce morbidity and mortality but also to allow delivery of full adapted-dose therapy which in turn impacts disease outcome. Administration should be based on ASCO and EORTC guidelines. Randomized phase III trials have confirmed the potential benefit of these agents in elderly patients. Epoetin should be used with caution in these patients with comorbidities such as hypertension.
| Central Nervous System (CNS) prophylaxis
A recent retrospective evaluation was performed of CNS relapse in very elderly DLBCL patients aged 80 years or older treated in 2 prospective LYSA studies with miniCHOP therapy, associated with either rituximab or ofatumumab, another anti-CD20 monoclonal antibody. This study showed a very low incidence of CNS relapse (1.8% at 2 years) despite the lack of CNS prophylaxis. This led to the conclusion that the absence of prophylaxis does not have a dramatic impact on incidence of CNS relapse and that prophylaxis can be avoided in the very elderly given the potential for the negative impact of the associated toxicities.
| Therapeutic strategies for other lymphoma subtypes
While therapeutic strategies for treating very elderly DLBCL patients are becoming clearer, very few specific propositions have been made for the treatment of other aggressive lymphoma subtypes. Burkitt lymphoma is a major problem given the poorer results obtained with classical CHOP and the near impossibility of increasing the dose intensity except in "young elderly" patients, ie, between 60 and 65 or 68 years.
R-CHOP is recommended, and if patients fail it, palliative treatment is certainly the best option. Peripheral T-cell lymphoma is also difficult to treat because no standard has been defined for young patients. No
"better" regimen than CHOP has been recommended for patients with peripheral T-cell lymphoma.
| Future therapeutic prospects
The R-CHOP-based regimen represents the gold standard 
| CONCLUDING REMARKS
Age has been described as an adverse prognostic factor for survival of lymphoma patients, especially when other diseases are also present.
The poorer results seen in the very elderly patients may reflect, at least partially, the use of lower doses of chemotherapeutic agents. However, once a complete remission is reached, disease-free survival of very elderly patients does not differ from that of younger patients, emphasizing the critical importance of achieving this response outcome. As the adapted dose-CHOP plus rituximab regimen is very well tolerated, it is currently considered standard treatment in fit patients.
New immunochemotherapy agents in first-line should help increase the complete remission rate.
